Wed.May 07, 2025

article thumbnail

IVIG Can Cause Kidney Function Decline, Thromboembolism in Patients With Dermatological Conditions

Pharmacy Times

Intravenous immunoglobulin (IVIG) treatment for dermatologic conditions shows effectiveness but poses risks of kidney decline and thromboembolism, necessitating careful monitoring.

article thumbnail

Optimizing Pharma Websites with AI-Driven Search Strategies

Pharma Marketing Network

Pharmaceutical websites serve a dual purpose: delivering trusted medical content and capturing the attention of health care professionals (HCPs), patients, and researchers. However, traditional search functions often fall short. Visitors can’t find what they need, content goes unseen, and bounce rates increase. This is where AI-driven search can transform the user experience and drive real results for pharma marketers.

FDA
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

UK trumpets a trade deal with India - but pharma isn't happy

pharmaphorum

Various industries have welcomed news of a trade deal between the UK and India, but Britain's pharma sector isn't among them

article thumbnail

Fierce Healthcare - Untitled Article

Fierce Healthcare

CMS is notifying insurers Congress may appropriate money toward cost-sharing reduction payments, causing upheaval in the Affordable Care Act market,

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Gilead’s Entry Inhibitor for Chronic Hepatitis Delta Demonstrates Durable Virologic Suppression Post-Treatment

PharmExec

Results from the Phase III MYR301 trial show that 36% of patients who achieved undetectable hepatitis delta virus levels when treated with bulevirtide maintained suppression for nearly two years.

article thumbnail

Fierce Healthcare - Untitled Article

Fierce Healthcare

Oscar Health's stock increased by 30% after its first quarter earnings, but company executives weighed in on the potential adverse consequences of cost-sharing reductions, ACA enhanced subsidy expirations and a shortened enrollment window.

More Trending

article thumbnail

White House withdraws nomination of a former Fox News contributor for U.S. surgeon general

STAT

WASHINGTON — The White House is withdrawing the nomination of former Fox News medical contributor  Janette Nesheiwat  for U.S. surgeon general, marking at least the second health-related pick from President  Donald Trump  to be pulled from Senate consideration. The withdrawal was confirmed by two people familiar with the matter.

article thumbnail

Low-Dose Chlorthalidone Granted FDA Approval for Treatment of Adults With Hypertension

Pharmacy Times

The 12.5-mg dose tablet enhances hypertension treatment options and reduces adverse effects for patients.

FDA
article thumbnail

New data could move Enhertu into early breast cancer

pharmaphorum

AstraZeneca and Daiichi Sankyo's Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage breast cancer for the first time

article thumbnail

Asembia AXS25: Emotional Support Transforms Specialty Pharmacy Patient Care

Pharmacy Times

Specialty pharmacy experts discuss how emotional support, addressing patient loneliness, and peer-to-patient programs can significantly improve medication adherence and patient care.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

AI trained on NHS data 'may predict ill health in advance'

pharmaphorum

An AI model is being piloted at a national scale for the first time, but will it be able to predict future health risks reliably?

article thumbnail

Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand

Pharmaceutical Technology

Novo Nordisk has cut its sales and profits forecasts for 2025 due to lower demand in the US for blockbuster weight loss and diabetes drugs.

article thumbnail

Asembia 2025: FDA Uncertainty Sparks Shift Toward Outsourced Pharma Support

Pharmaceutical Commerce

Will Pih, co-founder, Two Labs, explains how ongoing regulatory uncertainty is slowing clinical trial activity and hiring across the industry, prompting greater reliance on specialty pharmacy services and outsourced support.

article thumbnail

Asembia 2025: GLP-1 Drugs Reshape Reimbursement and Coverage Models

PharmExec

Doug Long, VP, industry relations, IQVIA, discusses how soaring demand for GLP-1 therapies is driving reimbursement challenges, shifting distribution models, and expanding the drugs potential into new therapeutic areas.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Pharma Pulse 5/7/25: Teva Pharmaceutical’s Branded Drugs Boost First Quarter Profit, Theriva Biologics Announces Positive VIRAGE Phase IIb Results

Pharmaceutical Commerce

Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.

article thumbnail

Health equity can be a competitive advantage: What pharma leaders need to know

pharmaphorum

As NICE begins to incorporate health equity into drug reimbursement decisions, forward-looking pharmaceutical companies have a chance to lead aligning innovation with access drivers and gaining a competitive edge in a changing global landscape.

article thumbnail

FDA grants RMAT status to Opus Genetics’ OPGx-LCA5 gene therapy

Pharmaceutical Technology

The US FDA has granted regenerative medicine advanced therapy (RMAT) designation to Opus Genetics gene therapy OPGx-LCA5

FDA
article thumbnail

Pharma Marketing Strategies That Actually Drive Results

Pharma Marketing Network

In an era where attention spans are shorter and healthcare stakeholders are increasingly digital-first, executing pharma marketing strategies that truly deliver ROI is both a challenge and a necessity. How do pharmaceutical brands cut through the clutter, earn HCP trust, and engage patients effectively? The answer lies in combining proven fundamentals with innovative tools and omnichannel integration.

FDA
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Sarepta shares fall amid FDA’s CBER appointment and weak Elevidys sales

Pharmaceutical Technology

Sareptas stock dropped by 26% after the FDA named a vocal critic of its gene therapy programme to lead its biologics division.

FDA
article thumbnail

With TV ads under threat, here’s how pharma can leverage social media

PharmaVoice

RFK Jr.’s plan to ban TV advertising may shift more marketing attention to online platforms.

article thumbnail

FDA plans to expand unannounced inspections of foreign drug plants 

Pharmaceutical Technology

This move comes a day after President Trump signed an executive order to streamline approval processes for domestic plants.

FDA
article thumbnail

UPMC's Innovative Approach to Heart Failure Care: Collaboration and Patient/Member-Centered Care Management

Pharmacy Times

UPMC enhances care for patients with heart failure through integrated pharmacy and cardiology team collaboration.

article thumbnail

Asembia 2025: GLP-1 Drugs Reshape Reimbursement and Coverage Models

Pharmaceutical Commerce

Doug Long, VP, industry relations, IQVIA, discusses how soaring demand for GLP-1 therapies is driving reimbursement challenges, shifting distribution models, and expanding the drugs potential into new therapeutic areas.

article thumbnail

Expert: Navigating the Next Decade of Market Growth and Innovation for Biosimilars

Pharmacy Times

Dracey Poore explores the future of biosimilars, emphasizing the need for increased adoption.

article thumbnail

Asembia 2025: FDA Uncertainty Sparks Shift Toward Outsourced Pharma Support

PharmExec

Will Pih, co-founder, Two Labs, explains how ongoing regulatory uncertainty is slowing clinical trial activity and hiring across the industry, prompting greater reliance on specialty pharmacy services and outsourced support.

article thumbnail

Study: Predictive CAD Model Outperforms Standard Practice in Estimating Individual Risk

Pharmacy Times

The coronary artery disease (CAD) predictive model help health care professionals tailor personalized treatment methods for patients.

article thumbnail

LivaNova’s aura6000 System Demonstrates High Response Rate in Moderate to Severe Obstructive Sleep Apnea

PharmExec

The aura6000 system showed a 65% responder rate at 12 months in patients with obstructive sleep apnea, defined as achieving at least a 50% reduction in apnea-hypopnea index.

article thumbnail

AI at the Counter: How Artificial Intelligence is Shaping the Future of Pharmacy Practice

Pharmacy Times

AI transforms pharmacy practice by streamlining workflows and enhancing patient care, while pharmacists adapt to new roles and challenges in health care.

article thumbnail

Acyclovir Versus Valacyclovir – What’s the Difference?

Med Ed 101

When treating herpes simplex virus (HSV) or varicella-zoster virus (VZV), two antiviral agents commonly used are acyclovir and valacyclovir. While both medications are effective, understanding their pharmacokinetic profiles, dosage forms, and clinical uses can help healthcare providers make the best choice for each patient. In this blog post, I will highlight the most important differences […] The post Acyclovir Versus Valacyclovir – What’s the Difference?

article thumbnail

STAT+: Compounders lose legal battle with FDA over removal of Eli Lilly’s weight loss drug from a shortage list

STAT

A federal judge has sided with the U.S. Food and Drug Administration over a decision last year to remove two Eli Lilly drugs — the Zepbound weight loss medicine and the Mounjaro diabetes treatment — from a shortages list kept by the agency. The move means that patients will no longer have access to cheaper versions from compounding pharmacies.

article thumbnail

Time Horizon: An Early Career Perspective

Pharmacy Times

The time frame concept is an underappreciated through line in most planning efforts.

article thumbnail

STAT+: Flatiron Health veterans raise $25 million for AI tool to forecast drug toxicity

STAT

In January, San Francisco’s Union Square was bustling with hordes of drug developers and investors, pounding the pavement on their way from meeting to meeting. But Rohan Ganesh, an investor at the VC firm Obvious Ventures, wasn’t among them. He only agreed to hear one company’s pitch during this year’s J.P. Morgan Healthcare Conference.

article thumbnail

Biofrontera and Almirall Launch Social Media Campaign for Actinic Keratosis

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.